Orizaba-Chávez B, Alba-Jasso GA, Ocharán-Hernández ME

Language: Spanish
References: 14
Page: 59-66
PDF size: 159.21 Kb.

ABSTRACT

Progesterone is a hormone that has multiple functions and although it has been already more than 80 years was isolated for the first time, is a molecule that has been described recently as its effects and mechanisms action. Today has many applications in different conditions of gynecology and obstetrics: such as threatened abortion, preterm birth prevention, menstrual disorders, luteal phase support, infertility and its various treatments of high or low complexity so it is very interesting to know the different compounds and their behavior once they enter the body so it will review its pharmacokinetic aspects.

REFERENCES

1. Trunk A. Biochemistry in wartime: the life and lessons of adolf butenandt 1936-1946. Minerva 2006: 285-306.

2. Borling NE. The excretion of pregnandiol in the urine in threatened abortion. Acta Endocrilon 22: 49-54.

3. NAMS. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause J N Am Menopause Society 2010; 17(2): 242-55.

4. King RJ, Whitehead MI. Assessment of the potency of orally administered progestins in women. Fertil and Steril 1986; 46: 1062-6. Cuadro 6. Bioequivalencias. Medroxiprogesterona 2.5 mg Progesterona micronizada 100 mg (1 cáp) Medroxiprogesterona 5 mg Progesterona micronizada 200 mg (2 cáp) Medroxiprogesterona 10 mg Progesterona micronizada 300 mg (3 cáp) Medroxiprogesterona 50 mg Progesterona micronizada 400 mg (4 cáp) Progesterona oleosa parenteral 100 mg Progesterona micronizada 400 mg (4 cáp)

5. Daniel AR, Gaviglio AL, Czaplicki LM, et al. The progeserone receptor hinge región regulares the kinetics of transcriptional responses through acetylation, phosphorylation, and nuclear retention. Mol Endocrinol 2010; 24(11): 2126-38.

6. Rekawiecki R, Kotwika KJ. Nuclear progesterone receptor isoforms and their functions in the female reproductive tract. Pol J Vterin Scien 2011: 14(1): 149-58.

7. Benitez R, Campodonico I, Roos A, et al. Bidisponibilidad y absorción de progesterona micronizada por vía oral en mujeres fértiles, con dosis única diaria. Rev Chil Obstet Ginecol 2001; 66(4): 255-61.

8. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002; 9(1): 6-15.

9. Nahoul K, et al. Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration or estradiol or progesterone. Maturitas 1993; 16; 185-202.

10. Hemauer SJ, Yan R, Patrikeeva SL, et al. Transplacental transfer and metabolism of 17 alfa-hydroxyprogesterone caproate. Am J Obstet Gynecol 2008; 199: 169.e1-169.e5.

11. Lignieres B. Orla micronized progesterone. Clin Therapeut 1999; 21: 41-60.

12. Ransom CE, Murtha AP. Progesterone for preterm birth prevention. Obstet Gynecol Clin N Am 2012; 39: 1-16.

13. Miles RA, Paulson RJ, Lobo RA, et al. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994; 62(3): 485-90.

14. How HY, Sibai BM. Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety. Therapeutics and Clinica Risk Management 2009; 5: 55-64.